Alvotech (NASDAQ:ALVO) Shares Gap Up – What’s Next?

Alvotech (NASDAQ:ALVO) gapped up prior to trading on Tuesday. The stock had previously closed at $5.03, but opened at $5.40. Alvotech shares last traded at $5.2360, with a volume of 438,353 shares changing hands.

Key Stories Impacting Alvotech

Here are the key news stories impacting Alvotech this week:

• Positive Sentiment: The FDA approved Alvotech’s Process 2.0 for SIMLANDI manufacturing at its Reykjavik facility. The process more than doubles drug-substance output per batch while maintaining product quality, safety and efficacy. Alvotech receives FDA approval for new SIMLANDI manufacturing process
• Positive Sentiment: The higher-yield process allows Alvotech to produce the same amount of drug substance in fewer batches, freeing manufacturing capacity for other biosimilars and improving its ability to meet partner demand. The approval follows a separate recent FDA authorization for additional manufacturing capacity. Alvotech shares rise after FDA approves Simlandi manufacturing process
• Neutral Sentiment: The manufacturing approval strengthens Alvotech’s operational position and supply reliability, but the company’s broader financial benefit will depend on commercial demand, pricing, execution and the performance of its biosimilar portfolio. Alvotech wins FDA approval for manufacturing upgrade
• Negative Sentiment: Zacks added ALVO to its Rank #5, or “Strong Sell,” list. The ranking may weigh on sentiment by signaling unfavorable expectations relative to Zacks’ quantitative criteria, offsetting some of the optimism from the FDA announcement. New Strong Sell stocks for October 21st

Analyst Ratings Changes

A number of brokerages have recently commented on ALVO. UBS Group set a $8.00 price objective on Alvotech in a research report on Wednesday, September 16th. Evercore initiated coverage on Alvotech in a report on Friday, August 14th. They issued an “outperform” rating on the stock. Bank of America started coverage on Alvotech in a research report on Monday, August 24th. They set a “buy” rating and a $7.00 target price on the stock. Weiss Ratings raised Alvotech from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, October 6th. Finally, Barclays raised Alvotech from an “underweight” rating to an “overweight” rating and upped their target price for the company from $4.00 to $8.00 in a report on Wednesday, September 16th. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $8.50.

Alvotech Price Performance

The firm has a market cap of $1.55 billion, a price-to-earnings ratio of -8.41 and a beta of 0.20. The stock’s fifty day moving average price is $5.24 and its 200-day moving average price is $4.15.

Alvotech (NASDAQ:ALVO) last posted its quarterly earnings data on Thursday, August 20th. The company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.06). The company had revenue of $106.00 million for the quarter, compared to analysts’ expectations of $103.00 million. As a group, equities research analysts predict that Alvotech will post -0.01 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Citadel Advisors LLC purchased a new stake in Alvotech in the 2nd quarter worth about $6,376,000. Renaissance Technologies LLC boosted its position in Alvotech by 146.9% during the 1st quarter. Renaissance Technologies LLC now owns 63,200 shares of the company’s stock worth $217,000 after acquiring an additional 37,600 shares during the period. Finally, Ulland Investment Advisors LLC grew its stake in Alvotech by 5.0% during the 3rd quarter. Ulland Investment Advisors LLC now owns 115,000 shares of the company’s stock valued at $667,000 after acquiring an additional 5,500 shares in the last quarter.

Alvotech Company Profile

Alvotech is a biotechnology company headquartered in Reykjavík, Iceland, focused on developing and manufacturing biosimilar medicines. Biosimilars are biologic products designed to be highly similar to already approved reference medicines and are intended to expand patient access to complex treatments at potentially lower costs.

The company uses an integrated research, development and manufacturing model and concentrates on therapeutic areas including immunology, ophthalmology, oncology and bone health.